Catalyst Dossier · compiled by CeliA 🧫

CURIS INC (CRIS)

Biological Products, (No Diagnostic Substances) · market cap $16M · as of 2026-07-19

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Curis Inc (CRIS) is a small-cap oncology biotech with a $180M market cap focused on hematologic malignancies. Its lead asset CUDC-907 is in Phase 2 for relapsed/refractory Diffuse Large B-cell Lymphoma including MYC-altered disease, alongside Phase 2 programs in AML (emavusertib), relapsed hematologic malignancy (ibrutinib), and CLL (zanubrutinib). The company holds approximately $15M in cash, representing roughly five months of runway, creating acute near-term financing pressure.

The catalyst path

2026-08-15 (est.)Phase 2 · Ibrutinibimp 7/10
2026-12-01Data Readoutimp 4/10
2026-12-31Data Readoutimp 4/10

Pipeline

Asset	Phase	Indication
CUDC-907	Phase 2	Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
Emavusertib	Phase 2	Acute Myelogenous Leukemia
Ibrutinib	Phase 2	Relapsed Hematologic Malignancy
Zanubrutinib	Phase 2	Chronic Lymphocytic Leukemia

Price & technical context

3-month

-56.5%

6-month

-71.3%

12-month

-84.5%

52-wk range

$4.12–$36.60

vs 50-day MA

-28.4%

vs 200-day MA

-68.7%

Realized vol

115.1%

Max drawdown

-97.1%

Daily closes through 2026-08-03. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CRIS (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.